

for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology



Loss of microRNA-155 Protects the Heart from Pathological Cardiac Hypertrophy

Circulation Research 2014, May 9th

Seok, Hee Young; Chen, Jinghai; Kataoka, Masaharu; Huang, Zhan-Peng; Ding, Jian et al.

Martin Köcher



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Structure



- 1. Backround Hypertrophy, miR155
- 2. Results:
 - #1 preliminary
 - #2 miR155 knockout vs ...
 - #3 miR155 knockout vs ... ISOLATED CELL
 - #4 miR155 and JARID2
- 3. Summary
- 4. Discussion



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology



Backround



Cardiac Hypertrophy



- Physiological: adaptive response to growth signals
- Pathological hypertrophy: response to stress signals
- Risk factor for arrhythmia and sudden cardiac death
- Molecular pathways not fully understood

1. Frey, N. Et al, Circulation 109, 1580–9 (2004).



miRNAs



- Short non-coding RNAs
- Regulation at post-transcriptional level
- Regulate 30-60% of protein-coding genes²
- Binding to mRNA, multiple targets
 - Inhibiting translation
 - Inducing degradation

2. Filipowicz, W. et al, Nat Rev Genet. 9, 102-114 (2008)



miRNA155



- Big player among miRs
 - → multiple already known targets
- Critical role shown in: ³
 - Cardiovascular disease
 - Hematopoietic lineage differentiation
 - Immunity

Ankersmit Laboratory

in Thoracic Diseases

- Inflammation
- Viral infections
- Cancer
- Down Syndrome

3. Elton, et al. Gene 532, 1–12 (2013).



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

miRNA155



Cardiovascular System:

 expressed in atherosclerotic plaques and proinflammatory macrophage -

 $KO \rightarrow reduced \ plaque \ size^{-4}$

 Overexpression in human cardiomyocyte progenitor cells linked to protection from necrotic cell death in vitro ⁵

4. Nazari-Jahantigh M. Et al, J Clin Invest. (2012); 122:4190–4202.
5. Liu J. Et al, J Cell Mol Med. 2011; 15:1474–1482.



miRNA155



Cardiovascular System:

- Endogenous inhibition attenuated cardiac infiltration by monocyte-macrophages ⁶
- In vivo function in cardiomyocyte hypertrophy was reported ⁷

6. Corsten MF. Et al, Circ Res.2012; 111:415–425.7. Heymans S. Et al, Circulation. 2013; 128:1420–1432



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology



RESULTS #1 preliminary



Expression in mice heart



Method: qPCR analyses

-increased in postnatal day 7

-highest in 15 month old mice


-important for

Ankersmit Laboratory

for Diagnosis & Regeneration in Thoracic Diseases

& Applied Immunolog

adult heart /remodeling?






for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Distribution



Method: qPCR analyses, Adult mouse hearts
→ miR155 mainly expressed in cardiomyocytes





Approach



Stimulation for hypertrophy was done in two ways:

Transverse Aortic Constriction

Calcineurin Transgenetic Mice

generated by Drs. Molkentin and Olson, were obtained from the Jackson lab(Tg(Myh6-Ppp3ca)37Eno)



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology Alteration in Hypertrophy



Method: qPCR analyses

-Decreased Expression stimulated by pressure overload

-No Alteration in Transgene mice

1.5 expression * NS P=0.07 1.0 **Relative miR-155** 0.5 0.0








MiR155 is putatively involved in the remodeling mechanism \rightarrow further investigation: miR155 knockout mice.


Normal mouse development and heart function under physiological conditions within miR155 null mice compared to their wildtype littermates.



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology Knockout mice vs. Wild type











for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Biometric Alteration











for Diagnosis & Regeneration in Thoracic Diseases

& Applied Immunology

Hypertrophic/ functional Markers











for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Biometric Alteration













for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology









Overcoming the limitation




miR155 apparently does affect the formation of a hypertrophic heart in mice, since :

 KO-mice show with both stressors less signs of hypertrophy in every way that was examined

But: miR155 is involved in many regulatory mechanisms, it still could be an effect of other points of its activity but in the cardiomyocytes.



for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology Knockout mice vs. Wild type MEDIZIN UNIVERS WIEN







for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Individual Cells **WT**



KO





α-Actinin/DAPI

Ctrl






for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Individual Cells









for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Individual Rat-Cells Ctrl Inhibitor



miR-155 Inhibitor






Ctrl





Individual Cells








for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology

Individual Cells







for Diagnosis & Regeneration in Thoracic Diseases & Applied Immunology Knockout mice vs. Wild type




RESULTS #4 miR155 and JARID2



Role of Jarid2



- Previously studies examined a role in cardiac hypertrophy
- Canonical target in T-lymphocytes
- Simulations expected it in cardiomyocytes as well





Ankersmit


Laboratory

for Diagnosis & Regeneration in Thoracic Diseases

& Applied Immunol

Histologic insight on effects of Jarid2


Neonatal mouse cardiomyocytes













Ankersmit


Laboratory

for Diagnosis & Regeneration in Thoracic Diseases

& Applied Immunole

Histologic insight on effects of Jarid2


Neonatal rat cardiomyocytes













Role of Jarid2



 \rightarrow Jarid2 knockdown de-represses this loss-of miR-155 phenotype when treated with PE

Also ANF and β-MHC expression was partly restored

Results were confirmed with ratcardiomyocytes



Summary



- miR-155 is required for the development of cardiac hypertrophy in response to stress
- Inhibition of miR-155 protects cardiac function in a mouse model of cardiac hypertrophy.
- miR-155 could be a therapeutic target for the treatment of pathological cardiac hypertrophy.
- Jarid2 was identified as a direct miR-155 target that mediates its function in cardiomyocytes



Discussion



- β-MHC mutations involved in 40% of hypertrophic heart diseases – alterations in miR155 effects? ⁸
- Expression pattern (especially miR155) differs strongly from neonatal to adult → only neonatal cells were isolated
- Remodeling necessary to a certain point adverse effects?

8. Blankenburg, R. et al., Circ. Res. 115, 227–237 (2014).



Discussion



- Future: more specific miR155 knockout
- Inhibition of Jarid2 could partly rescue the effect of mir155 loss
- But Jarid2-inhibition reduced PE-induced hypertrophy → distinct role of Jarid2
- Wide field of not yet known miR155 derived mechanisms in the heart
- Putative therapeutic target for cardiac defects